Affiliations: Division of Brain Diseases, Center for Biomedical Sciences, Korea National Institute of Health, Osong, Republic of Korea
Correspondence:
[*]
Correspondence to: Jae-Pil Jeon, 187 Osongsaengmyeong-2-ro, Osong-eup, Heungdeok-gu, Cheongju-si, Chungcheongbuk-do 28159, Republic of Korea. Tel.: +82 43 719 8632; Fax: +82 43 719 8602; E-mail: jaepiljeon@hanmail.net.
Note: [1] These authors made equal contributions
Abstract: Chronic viral infection is implicated in cognitive decline and Alzheimer’s disease (AD). Our goal was to identify biomarkers for the development of amnestic mild cognitive impairment (aMCI) from cognitively normal state. To accomplish this, we analyzed plasma IgG levels against Epstein-Barr virus (EBV) and herpes simplex virus 1 (HSV-1) in study subjects with incident aMCI (Converter) and normal cognitive function (NC Control) who did or did not convert from cognitively normal state to aMCI during the 2-year follow-up period, respectively. The Converter group exhibited elevated levels of anti-EBV IgG antibodies in the post-follow-up phase (aMCI state) compared to the pre-follow-up phase (cognitively normal state), but not the NC Control group. In contrast, the total IgG level was not significantly changed over the follow-up period. Moreover, elevated anti-EBV IgG levels were significantly associated with CDR scales and total CERAD scores in the Converter group. These results suggest that EBV infection or its related host immune response is linked to cognitive decline. Thus, an EBV antibody level may be used as a potential biomarker for assessing the risk of aMCI development, implying a role for chronic EBV infection in AD pathogenesis.
